Acute Myeloid Leukemia Therapeutics Market

研究執行與發布：Coherent Market Insights　·　發布日期 2026-09-09　·　250 頁
由量子訊息有限公司（Quantum Information）在台灣代理銷售與提供授權諮詢。

2026 年市場規模: USD 3.76 Bn
2033 年預估規模: USD 7.23 Bn
年複合成長率 CAGR: 9.8%

以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。

完整報告名稱與涵蓋範圍

Acute Myeloid Leukemia Therapeutics Market, By Disease Type (Myeloblastic Leukemia, Promyelocytic Leukemia, Myelomonocytic Leukemia, Monocytic Leukemia, Others), By Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy, Combination Therapy, Supportive Care), By Route of Administration (Parenteral, Oral), By End User (Hospitals, Specialty Oncology Centers, Clinics and Ambulatory Care Centers, Homecare Settings, Others), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)

報告摘要

The global acute myeloid leukemia therapeutics market is estimated to be valued at USD 3.76 Bn in 2026 and is expected to reach USD 7.23 Bn by 2033, exhibiting a compound annual growth rate (CAGR) of 9.8% from 2026 to 2033. Acute Myeloid Leukemia (AML) is a lethal blood cancer that arises in the bone marrow. It is an uncontrolled growth of immature myeloid cells with interference to the normal blood cell production. The molecular heterogeneity and association with multiple genetic alterations makes AML a complex disease requiring more specialized treatment strategies. The acute myeloid leukemia treatment landscape has moved from chemotherapy to targeted therapy, immunotherapies and precision-based therapies, with the addition of FLT3, IDH1/2, BCL-2 and menin inhibitors broadening the treatment options. Key drivers for the global acute myeloid leukemia therapeutics market include the rising burden of the disease, clinical research, and investment in new therapies. Market Dynamics The global acute myeloid leukemia therapeutics market is driven by the increasing prevalence of AM acute myeloid leukemia in aging populations, advancements in genomic profiling, and the enhanced application of mutation-specific targeted therapy. Moreover, expedited regulatory pathways are enabling the development and commercialization of new treatments, and greater healthcare investment is improving the access to cutting-edge oncology care. However, the growth of acute myeloid leukemia therapeutics market is limited by factors such as high treatment cost, molecular complexity, resistance to drugs and the recurrence of the disease. Nevertheless, significant opportunities exist in growing pipeline of menin inhibitors, antibody-drug conjugates, bispecific antibodies, CAR-T therapies and new combination regimens. Key Features of the Study • This report provides in-depth analysis of the global acute myeloid leukemia therapeutics market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players • It profiles key players in the global acute myeloid leukemia therapeutics market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies • Key companies covered as a part of this study include AbbVie Inc., Astellas Pharma Inc., Bristol Myers Squibb Company, Daiichi Sankyo Company, Limited, Jazz Pharmaceuticals plc, Novartis AG, Pfizer Inc., Otsuka Pharmaceutical Co., Ltd., Rigel Pharmaceuticals, Inc., and Servier Pharmaceuticals LLC • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics • The global acute myeloid leukemia therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global acute myeloid leukemia therapeutics market Market Segmentation • Disease Type Insights (Revenue, USD Bn, 2021 - 2033) o Myeloblastic Leukemia o Promyelocytic Leukemia o Myelomonocytic Leukemia o Monocytic Leukemia o Others • Treatment Type Insights (Revenue, USD Bn, 2021 - 2033) o Chemotherapy o Targeted Therapy o Immunotherapy o Combination Therapy o Supportive Care • Route of Administration Insights (Revenue, USD Bn, 2021 - 2033) o Parenteral o Oral • End User Insights (Revenue, USD Bn, 2021 - 2033) o Hospitals o Specialty Oncology Centers o Clinics and Ambulatory Care Centers o Homecare Settings o Others • Regional Insights (Revenue, USD Bn, 2021 - 2033) o North America  U.S.  Canada o Latin America  Brazil  Argentina  Mexico  Rest of Latin America o Europe  Germany  U.K.  Spain  France  Italy  Russia  Rest of Europe o Asia Pacific  China  India  Japan  Australia  South Korea  ASEAN  Rest of Asia Pacific o Middle East  GCC Countries  Israel  Rest of Middle East o Africa  South Africa  North Africa  Central Africa • Key Players Insights o AbbVie Inc. o Astellas Pharma Inc. o Bristol Myers Squibb Company o Daiichi Sankyo Company, Limited o Jazz Pharmaceuticals plc o Novartis AG o Pfizer Inc. o Otsuka Pharmaceutical Co., Ltd. o Rigel Pharmaceuticals, Inc. o Servier Pharmaceuticals LLC

授權報價

Single User Price	$4,500 USD
Enterprise License	$10,000 USD

目錄 Table of Contents

Table of Contents 1. Research Objectives and Assumptions o Research Objectives o Assumptions o Abbreviations 2. Market Purview o Report Description  Market Definition and Scope o Executive Summary  Global Acute Myeloid Leukemia Therapeutics Market, By Disease Type  Global Acute Myeloid Leukemia Therapeutics Market, By Treatment Type  Global Acute Myeloid Leukemia Therapeutics Market, By Route of Administration  Global Acute Myeloid Leukemia Therapeutics Market, By End User  Global Acute Myeloid Leukemia Therapeutics Market, By Region 3. Market Dynamics, Regulations, and Trends Analysis o Market Dynamics o Impact Analysis o Key Highlights o Regulatory Scenario o Product Launches/Approvals o PEST Analysis o PORTER’s Analysis o Market Opportunities o Industry Trends 4. Global Acute Myeloid Leukemia Therapeutics Market, By Disease Type, 2021-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Myeloblastic Leukemia  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Promyelocytic Leukemia  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Myelomonocytic Leukemia  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Monocytic Leukemia  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Others  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) 5. Global Acute Myeloid Leukemia Therapeutics Market, By Treatment Type, 2021-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Chemotherapy  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Targeted Therapy  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Immunotherapy  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Combination Therapy  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Supportive Care  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) 6. Global Acute Myeloid Leukemia Therapeutics Market, By Route of Administration, 2021-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Parenteral  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Oral  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) 7. Global Acute Myeloid Leukemia Therapeutics Market, By End User, 2021-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Hospitals  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Specialty Oncology Centers  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Clinics and Ambulatory Care Centers  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Homecare Settings  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Others  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) 8. Global Acute Myeloid Leukemia Therapeutics Market, By Region, 2021 - 2033, Value (USD Bn) o Introduction  Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Bn)  Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)  Regional Trends o North America  Introduction  Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By End User,2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn) o U.S. o Canada o Latin America  Introduction  Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By End User,2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn) o Brazil o Argentina o Mexico o Rest of Latin America o Europe  Introduction  Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By End User,2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn) o Germany o U.K. o Spain o France o Italy o Russia o Rest of Europe o Asia Pacific  Introduction  Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By End User,2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn) o China o India o Japan o Australia o South Korea o ASEAN o Rest of Asia Pacific o Middle East  Introduction  Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By End User,2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn) o GCC Countries o Israel o Rest of Middle East o Africa  Introduction  Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By End User,2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn) o South Africa o North Africa o Central Africa 9. Competitive Landscape o AbbVie Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Astellas Pharma Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Bristol Myers Squibb Company  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Daiichi Sankyo Company, Limited  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Jazz Pharmaceuticals plc  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Novartis AG  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Pfizer Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Otsuka Pharmaceutical Co., Ltd.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Rigel Pharmaceuticals, Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Servier Pharmaceuticals LLC  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies 10. Analyst Recommendations o Wheel of Fortune o Analyst View o Coherent Opportunity Map 11. References and Research Methodology o References o Research Methodology o About us *Browse 32 market data tables and 28 figures on ‘Acute Myeloid Leukemia Therapeutics Market' - Global forecast to 2033

提及公司

AbbVie Inc.Astellas Pharma Inc.Bristol Myers Squibb CompanyDaiichi Sankyo Company, LimitedJazz Pharmaceuticals plcNovartis AGPfizer Inc.Otsuka Pharmaceutical Co., Ltd.Rigel Pharmaceuticals, Inc.Servier Pharmaceuticals LLC

常見問題

這份報告可以先索取樣本嗎？

可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算？

報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付？如何付款？

一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。

量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・聯絡我們